Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dul

Showing results (221-230 of 230) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 230 results.
Surgical Oncology|November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancerJames V Pellicane, Peter D Beitsch, David T Rock, et al.
JCO Precision Oncology|September 15, 2022
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant TherapyPat W Whitworth, Peter D Beitsch, Mary K Murray, et al.
Assay and Drug Development Technologies|June 19, 2013
Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylationMartin Brandt, Lawrence M Szewczuk, Hong Zhang, et al.
Immunotherapy Advances|August 3, 2022
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetesD Tatovic, M A McAteer, J Barry, et al.
JCO Precision Oncology|April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene SignaturePat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Annals of Surgical Oncology|April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerPat Whitworth, Peter D Beitsch, James V Pellicane, et al.
Journal of Medicinal Chemistry|January 5, 2007
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitorsKrista B Goodman, Haifeng Cui, Sarah E Dowdell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 27, 2024
White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skinMaria Dul, Mohammed Alali, Mahmoud Ameri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 12, 2023
Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) productMaria Dul, Mohammed Alali, Mahmoud Ameri, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activityRobert A Stavenger, Haifeng Cui, Sarah E Dowdell, et al.
Pageof 23

Showing results (221-230 of 230) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 230 results.
Surgical Oncology|November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancerJames V Pellicane, Peter D Beitsch, David T Rock, et al.
JCO Precision Oncology|September 15, 2022
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant TherapyPat W Whitworth, Peter D Beitsch, Mary K Murray, et al.
Assay and Drug Development Technologies|June 19, 2013
Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylationMartin Brandt, Lawrence M Szewczuk, Hong Zhang, et al.
Immunotherapy Advances|August 3, 2022
Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetesD Tatovic, M A McAteer, J Barry, et al.
JCO Precision Oncology|April 27, 2022
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene SignaturePat W Whitworth, Peter D Beitsch, James V Pellicane, et al.
Annals of Surgical Oncology|April 5, 2022
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast CancerPat Whitworth, Peter D Beitsch, James V Pellicane, et al.
Journal of Medicinal Chemistry|January 5, 2007
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitorsKrista B Goodman, Haifeng Cui, Sarah E Dowdell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 27, 2024
White paper: Understanding, informing and defining the regulatory science of microneedle-based dosage forms that are applied to the skinMaria Dul, Mohammed Alali, Mahmoud Ameri, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 12, 2023
Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) productMaria Dul, Mohammed Alali, Mahmoud Ameri, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activityRobert A Stavenger, Haifeng Cui, Sarah E Dowdell, et al.
Pageof 23